It seems that nowadays there can’t be any problems with buying medicaments – there are lots of pharmacies within walking distance. And yet, online pharmacies are becoming more and more popular. There are numerous reasons that explain this fact, in one word – it is «convenient».
My Canadian Pharmacy is a telling example of prosperous and reliable online service providing high quality drugs and assistance. For almost 20 years we gained our reputation of trustworthy, favourable and convenient pharmaceutical supplier worldwide.
Here you can find not only a wide range of products, but also professional service. We use modern technologies that enable us control drugs quality offered for sale. My Canadian Pharmacy has almost everything: medicines, home medical equipment, hygiene products, medical products, health and beauty products, herbs, medications for children, health food – in short, everything that can be found in regular pharmacy.
In this article we would like to define our main advantages over regular pharmacies, so that you have clear idea about our service and put trust on us.
Twenty-four-hour schedule. It is very convenient, and not only in cases when you urgently need a medication at night. Modern life rhythm is that often people can find some time for themselves only at late evening or early morning hours. My Canadian Pharmacy allows making orders in the evening, early in the morning, at 3 am, on weekends, on holidays – whenever it suits you.
My Canadian Pharmacy offer medications and related products at lower prices than regular pharmacies. The reason is simple – all our costs are optimized, there is no need in leasing expensive premises, maintaining a large staff of pharmacists, as well as support staff (domestic assistants, etc.). Cost reduction allows setting minimal profit margin on medicines.
No need to visit regular pharmacy, you can just order necessary medications online on our website, and they will be delivered to you as soon as possible. This is especially important in case of lacking time or feeling unwell. Many of us suffered from painful conditions when it is difficult not only to get dressed and go out, but get out of bed; but these are the very moments we need medications. My Canadian Pharmacy solves this problem for you.
Assortment range is wider that at regular pharmacies. This concerned not only drugs, but also other goods: therapeutic cosmetics, newborn care products, etc. And if regular pharmacy rare gives opportunity get acquainted without haste with products offered and think carefully over your choice, My Canadian Pharmacy allows reading in detail drugs or agents description, thinking as long as you wish and choosing the product you really need.
Privacy. Questions concerning health are quite intimate and many people experienced that awkward moment when you need to explain loudly to pharmacist what you need, and it is especially uncomfortable when there is curious queue listening. My Canadian Pharmacy guarantees complete privacy.
But, of coarse, it is not without disadvantages. But they are few and the same as any other online pharmacy has.
- This disadvantage naturally comes out of previously observed advantages – temptation of self-medication is high. Each drug has instructions and descriptions; everyone, unfortunately, has experienced unsuccessful doctor examinations and consultations, and now believe that in most cases we are able to choose the right medicine by ourselves. It is important to responsibly take care of our health and remember that self-medication is unacceptable in serious situations.
Drug delivery usually takes some time. But there are situations when drug has to be taken immediately. Therefore, always ordering medicines in the Internet, you should specify delivery terms.
If you want to try to make a purchase online without any risk, we invite you to visit My Canadian Pharmacy www.my-medstore-canada.net website right mow. Our online pharmacy provides various drugs and medical cosmetics of highest quality, low prices and fast delivery all over the world!
The causes and implications of the recent chapter-11 bankruptcy filing of the largest miner and manufacturer of asbestos and asbestos-containing products in North America is understandably receiving wide review. The public statements of the company indicate that its decision was based on the potential economic loss created by present and future product-liability suits, and the data presented by them were generated by epidemiologic consultants using available scientific information. The appropriateness of the selection of data for this purpose, as well as the analysis and interpretation of these data, in addition to future proposals made to the bankruptcy court, must be examined carefully. There seems to be a surfeit of discussion regarding a possible role for government in compensating those with claims and a curious lack of interest in the question of how many claimants are really ill and which among these have asbestos-attributable diseases. Current proposals for legislation on federal compensation for asbestos-associated diseases, their effect on the litigation, and how it has been influenced by the bankruptcy proceedings are clearly areas in which the interface between scientific data and social policy is central.
As previously indicated, the setting of permissible limits of exposure to asbestos, primarily a workplace issue, depends upon the establishment of dose-response relationships, with subsequent determination of an acceptable level of risk. For the asbestos-associated diseases, this task would be immeasurably simpler if dose-response relationships were similar for all industrial processes, all fiber types, and all asbestos-induced diseases. Unfortunately, the evidence indicates substantial variability of relationships within these categories.
Compensation of Existing Disease
In examining current approaches to the compensation and prevention of asbestos-associated diseases, particular emphasis is placed on the utilization (or lack of it) of the biomedical scientific data base in accomplishing these objectives. It should be emphasized that, as with many other occupationally induced disorders, the asbestos-associated diseases are best dealt with by prevention through control of exposures to airborne concentrations of asbestos dust. In addition to the human costs of these diseases, no scheme of compensation can provide adequate disincentive for industry which would lead to the prevention of these conditions; this is due in large part to the long period of latency between relevant exposure and clinical manifestations of these diseases; however, recognizing that past exposures have produced these injuries, society must be committed to the provision of just resolution of claims by injured workers. Disease-specific approaches to federal legislation on compensation are not optimal in reaching the objective of equitable and timely awards for all workers who develop diseases as a consequence of their employment. The inadequacies of the legislation on black lung have received considerable attention and have been the subject of periodic controversy, often focusing on questions of cost effectiveness and equity. Currently, in the US Congress, legislation dealing with asbestos-associated diseases is being debated, undoubtedly related to overwhelming public and economic pressure. In recent months the opinion has often been expressed that the present system is strikingly inadequate in meeting the needs of individuals who have developed asbestos-associated diseases treated with My Canadian Pharmacy.
There has been inconstant reliance on scientific knowledge regarding the asbestos-related diseases in the formulation of public policy. Since the recognition of asbestos-related diseases in the 1930s, decisionmaking on public policy has frequently been at best obscurely related to the existing biomedical scientific data base. This disparity has probably increased in recent years, and at times, scientific considerations have been largely ignored in the process of formulating policy.
The asbestos-associated health effects have, during the past ten years, commanded a unique position in the awareness and concern of individuals and various groups in our society. This unprecedented interest has extended well beyond the medical, public health, and biomedical research professionals, and there is no occupational health issue (a special set of public health concerns) which has had as much potential for interaction between social scientists, research investigators, government officials, industrial management, labor organizations, and members of the legal profession. The effectiveness in utilizing an emerging scientific data base in dealing with the public policy issues has been strikingly variable. Ethical, economic, and other social implications have resulted from occupational exposure to asbestos, and it is likely that in the United States, we are currently at or near the peak effect in terms of the various manifestations of this impact.